Featured Trial
Pancreas Cancer Treatment

Featured Trial
Head and Neck Cancer Treatment

Featured Trial
Leukemia Treatment

Featured Trial
Prostate Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Resources for Active Trials

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
PRO Research Overview

Specialty Presentation:
Implementation Science

Latest News

November 16, 2023

Categories

Statement on the passing of Dr. Worta McCaskill-Stevens

November 15, 2023

Categories

Press Releases

Press Release: ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

November 7, 2023

Categories

ECOG-ACRIN Group Co-Chairs congratulate Dr. Monica Bertagnolli on her appointment as Director of the National Institutes of Health

October 19, 2023

Categories

The September/October News from ECOG-ACRIN blog is now available

October 17, 2023

Categories

News Stories

Associated Press runs international story to highlight the TMIST breast cancer screening trial

Tweets

ECOG-ACRIN Cancer Research Group Follow 6,271 5,956

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

; ECOG-ACRIN Cancer Research Group @eaonc ·

15h 1730315963592032317

#ClinicalTrial EA2222/PUMP, led by @michael_lidsky, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: https://bit.ly/ea2222-pump cc: @MichaelDAngeli2, @skmaithel, @AndreaCercek

Reply on Twitter 1730315963592032317 Retweet on Twitter 1730315963592032317 0 Like on Twitter 1730315963592032317 1 Twitter 1730315963592032317

; ECOG-ACRIN Cancer Research Group @eaonc ·

16h 1730300868635820108

EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: https://bit.ly/ea8192-trial #blcsm

Reply on Twitter 1730300868635820108 Retweet on Twitter 1730300868635820108 0 Like on Twitter 1730300868635820108 0 Twitter 1730300868635820108

; ECOG-ACRIN Cancer Research Group @eaonc ·

17h 1730285817422049336

The EA8211/SOAR clinical study is testing a new treatment approach for patients with #KidneyCancer that has spread to 2-5 other places in the body. Learn more: https://bit.ly/ea8211-study #kcsm

Reply on Twitter 1730285817422049336 Retweet on Twitter 1730285817422049336 0 Like on Twitter 1730285817422049336 0 Twitter 1730285817422049336

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1300

Participating Institutions

International Sites

15000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).